| Characteristics                  | Patients switched to DOAC (N = 62,620) | Patients not switched (N = 320,388) | P-value |
|---------------------------------|---------------------------------------|------------------------------------|---------|
| **Age**                         |                                       |                                    |         |
| Mean ± SD (N)                   | 71.7±10.5                             | 74.4±10.3                          |         |
| ≤ 50                            | 3.3% (2,090)                          | 2.7% (8,713)                       | <.001   |
| 51 - 60                         | 11.2% (7,005)                         | 8.3% (26,732)                      |         |
| 61 - 70                         | 27.6% (17,283)                        | 22.4% (71,849)                     |         |
| 71 - 80                         | 36.4% (22,786)                        | 36.4% (116,572)                    |         |
| > 80                            | 21.5% (13,456)                        | 30.1% (96,522)                     |         |
| **Sex**                         |                                       |                                    | 0.353   |
| Male                            | 57.6% (36,090)                        | 57.4% (184,007)                    |         |
| Female                          | 42.4% (26,530)                        | 42.6% (136,381)                    |         |
| **Race**                        |                                       |                                    | <.001   |
| White                           | 66.7% (41,751)                        | 69.4% (222,337)                    |         |
| Black                           | 3.4% (2,120)                          | 3.2% (10,163)                      |         |
| Other                           | 0.3% (183)                            | 0.3% (860)                         |         |
| **Hispanic or Latino Ethnicity**|                                       |                                    | <.001   |
| Yes                             | 2.4% (1,525)                          | 2.0% (6,525)                       |         |
| No                              | 97.6% (61,095)                        | 98.0% (313,863)                    |         |
| **Insurance Type**              |                                       |                                    | <.001   |
| None                            | 1.9% (1,197)                          | 2.3% (7,260)                       |         |
| Private                         | 51.8% (32,463)                        | 46.8% (150,010)                    |         |
| Medicare                        | 19.9% (12,482)                        | 23.1% (74,013)                     |         |
| Medicaid                        | 0.4% (253)                            | 0.4% (1,362)                       |         |
| Other                           | 0.6% (391)                            | 0.4% (1,135)                       |         |
| **Tobacco Use**                 |                                       |                                    | <.001   |
| Never                           | 36.1% (22,633)                        | 37.1% (118,999)                    |         |
| Characteristics                                      | Patients switched to DOAC (N = 62,620) | Patients not switched (N = 320,388) | P-value |
|-----------------------------------------------------|---------------------------------------|-------------------------------------|---------|
| Current                                             | 12.2% (7,659)                         | 10.4% (33,375)                      |         |
| Quit within past 12 months                         | 2.4% (1,513)                          | 1.8% (5,807)                        |         |
| Quit more than 12 months ago                       | 32.5% (2,0375)                       | 34.8% (111,353)                     |         |
| Tobacco screening not performed for medical reasons | 0.0% (0)                              | 0.0% (7)                            |         |
| **Alcohol Use**                                     |                                      |                                     | <.001   |
| None                                                | 13.4% (8,370)                         | 13.7% (43,943)                      |         |
| One or fewer alcoholic drinks per week              | 3.2% (2,027)                          | 2.8% (9,076)                        |         |
| 2 to 7 alcoholic drinks per week                    | 0.4% (250)                            | 0.5% (1,633)                        |         |
| 8 to 14 alcoholic drinks per week                   | 0.1% (75)                             | 0.2% (493)                          |         |
| 15 or more alcoholic drinks per week                | 0.1% (62)                             | 0.1% (304)                          |         |
| **Comorbidities**                                   |                                      |                                     |         |
| Hypertension (%)                                    | 78.5% (49,150)                       | 77.6% (248,640)                     | <.001   |
| Coronary artery disease (%)                         | 46.4% (29,074)                       | 49.9% (160,033)                     | <.001   |
| Unstable angina (%)                                 | 1.5% (908)                            | 1.8% (5,729)                        | <.001   |
| Stable angina (%)                                   | 7.4% (4,626)                          | 8.1% (26,099)                       | <.001   |
| Dyslipidemia (%)                                    | 62.5% (39,152)                       | 62.6% (200,542)                     | 0.739   |
| Congestive heart failure (%)                        | 26.5% (16,577)                       | 30.8% (98,771)                      | <.001   |
| Prior stroke or transient ischemic attack (%)       | 14.0% (8,758)                        | 12.3% (39,389)                      | <.001   |
| Prior systemic embolism (%)                         | 0.0% (0)                              | 0.0% (0)                            |         |
| Peripheral arterial disease (%)                     | 9.0% (5,629)                          | 9.4% (30,263)                       | <.001   |
| Diabetes mellitus (%)                               | 24.2% (15,123)                       | 23.8% (76,137)                      | 0.038   |
| Prior myocardial infarction (%)                     | 13.9% (8,735)                        | 14.8% (47,562)                      | <.001   |
| Prior coronary artery bypass graft (%)              | 7.7% (4,800)                          | 9.3% (29,688)                       | <.001   |
| Prior percutaneous coronary intervention (%)        | 9.3% (5,817)                          | 8.9% (28,591)                       | 0.003   |
| Characteristics                          | Patients switched to DOAC (N = 62,620) | Patients not switched (N = 320,388) | P-value |
|-----------------------------------------|--------------------------------------|------------------------------------|--------|
| **Atrial Fibrillation/Flutter Duration**|                                      |                                    | <.001  |
| First diagnosed                         | 6.0% (3,764)                         | 5.9% (18,779)                      |        |
| Paroxysmal                              | 19.9% (12,490)                       | 18.9% (60,677)                     |        |
| Persistent                              | 3.5% (2,187)                         | 4.2% (13,508)                      |        |
| Long-standing persistent                | 0.0% (0)                             | 0.0% (0)                           |        |
| Permanent                               | 0.6% (403)                           | 0.8% (2,532)                       |        |
| **Left Ventricular Ejection Fraction**   |                                      |                                    | <.001  |
| > 70                                    | 2.3% (1,425)                         | 2.3% (7,238)                       |        |
| 50 - 70                                 | 30.1% (18,834)                       | 31.6% (101,132)                    |        |
| 40 - 49                                 | 5.4% (3,404)                         | 6.1% (19,435)                      |        |
| 30 - 39                                 | 3.4% (2,129)                         | 3.8% (12,181)                      |        |
| < 30                                    | 2.6% (1,649)                         | 3.3% (10,728)                      |        |
| **Laboratory Results**                  |                                      |                                    |        |
| Hemoglobin A1c (%)                      |                                     |                                    | <.001  |
| Mean± SD (N)                            | 8.2±3.2 (844)                        | 9.1±3.5 (5,141)                    |        |
| Total cholesterol (mg/dL)               |                                     |                                    | <.001  |
| Mean± SD (N)                            | 161.3±40.0 (16,492)                  | 160.0±40.0 (85,149)                |        |
| High-density lipoprotein cholesterol (mg/dL) |                     |                                    | <.001  |
| Mean± SD (N)                            | 48.4±15.9 (15,816)                   | 47.1±15.4 (83,035)                 |        |
| Low-density lipoprotein cholesterol (mg/dL) |                           |                                    | 0.063  |
| Mean± SD (N)                            | 88.3±36.2 (16,676)                   | 87.7±35.0 (85,487)                 |        |
| International formalized ratio          |                                     |                                    | <.001  |
| Mean± SD (N)                            | 2.3±1.8 (15,404)                     | 2.4±2.0 (74,702)                   |        |
| **Renal Function Determined by Glomerular Filtration Rate** |                           |                                    | <.001  |
| ≥ 90                                    | 1.9% (1,214)                         | 1.3% (4,142)                       |        |
| 60 - 89                                 | 7.1% (4,425)                         | 5.5% (17,654)                      |        |
| Characteristics       | Patients switched to DOAC (N = 62,620) | Patients not switched (N = 320,388) | P-value |
|-----------------------|----------------------------------------|-------------------------------------|---------|
| 30 - 59               | 5.5% (3,420)                           | 5.2% (16,728)                      |         |
| 15 - 29               | 0.4% (262)                             | 0.6% (1,874)                       |         |
| < 15                  | 0.1% (35)                              | 0.2% (513)                         |         |
| **Risk Score**        |                                         |                                     |         |
| CHADS2                |                                         |                                     |         |
| Missing               | 0.0% (0)                               | 0.0% (0)                           |         |
| Mean± SD (N)          | 2.0±1.2                                | 2.1±1.2                            | <.001   |
| Median (Q1, Q3)       | 2.0 (1.0, 3.0)                         | 2.0 (1.0, 3.0)                     |         |
| Range (Min, Max)      | (0.0, 6.0)                             | (0.0, 6.0)                         |         |
| CHA2DS2-VASc          |                                         |                                     |         |
| Missing               | 0.0% (0)                               | 0.0% (0)                           |         |
| Mean± SD (N)          | 3.5±1.7                                | 3.7±1.6                            | <.001   |
| Median (Q1, Q3)       | 3.0 (2.0, 5.0)                         | 4.0 (3.0, 5.0)                     |         |
| Range (Min, Max)      | (0.0, 9.0)                             | (0.0, 9.0)                         |         |
| CHA2DS2-VASc score tertiles |                                   |                                     |         |
| Score 0 - 1           | 11.3% (7,083)                          | 8.5% (27,080)                      | <.001   |
| Score 2 - 3           | 39.6% (24,769)                         | 37.5% (119,992)                    |         |
| Score 4 or more       | 49.1% (30,768)                         | 54.1% (173,316)                    |         |
| **Bleeding Risk Score** |                                       |                                     |         |
| HAS-BLED              |                                         |                                     |         |
| Missing               | 0.0% (0)                               | 0.0% (0)                           |         |
| Mean± SD (N)          | 2.2±1.0                                | 2.2±0.9                            | 0.005   |
| Median (Q1, Q3)       | 2.0 (2.0, 3.0)                         | 2.0 (2.0, 3.0)                     |         |
| Range (Min, Max)      | (0.0, 7.0)                             | (0.0, 7.0)                         |         |
| **Medications**       |                                         |                                     |         |
| Aspirin (%)           | 49.9% (31,222)                         | 45.4% (145,400)                    | <.001   |
| P2Y12 inhibitor (%)   | 10.7% (6,703)                          | 8.1% (25,804)                      | <.001   |
| Any antiarrhythmic (%)| 22.4% (14,012)                         | 15.8% (50,603)                     | <.001   |
| Characteristics     | Patients switched to DOAC (N = 62,620) | Patients not switched (N = 320,388) | P-value |
|---------------------|----------------------------------------|-------------------------------------|---------|
| Amiodarone (%)      | 10.4% (6,498)                          | 6.8% (21,664)                       | <.001   |
| Dronedarone (%)     | 2.2% (1,385)                           | 0.9% (2,806)                        | <.001   |